Breaking News

BioVersys Gets EIB Funds to Address Antimicrobial Resistance

Financing supports development of BioVersys’ breakthrough hospital antibiotic therapy targeting Acinetobacter baumannii

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, signed a €20 million venture debt transaction. The financing supports the company’s research and development of a diverse pipeline of drugs that address antimicrobial resistance (AMR). AMR has resulted in the majority of antimicrobial therapies becoming obsolete, potentially resulting in a bacterial pandemic.   BV100, BioVersys’ breakt...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters